Cargando…

T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant

Detalles Bibliográficos
Autores principales:	Choi, Seong Jin, Kim, Dong-Uk, Noh, Ji Yun, Kim, Sangwoo, Park, Su-Hyung, Jeong, Hye Won, Shin, Eui-Cheol
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764507/ https://www.ncbi.nlm.nih.gov/pubmed/35043006 http://dx.doi.org/10.1038/s41423-022-00838-5

Ejemplares similares

Omicron Subvariants, Including BA.4 and BA.5, Substantially Preserve T Cell Epitopes of Ancestral SARS-CoV-2
por: Park, Kyemyung, et al.
Publicado: (2022)

Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1
por: Miller, Jessica, et al.
Publicado: (2023)

SARS-CoV-2 mutations, vaccines, and immunity: implication of variants of concern
por: Noh, Ji Yun, et al.
Publicado: (2021)

Limits of Monoclonal Antibody Treatment in Pregnant Women Complicated with COVID-19 Due to The Omicron Variant
por: Cha, Hyun-Hwa, et al.
Publicado: (2022)

Plasma Neutralization of the SARS-CoV-2 Omicron Variant
por: Schmidt, Fabian, et al.
Publicado: (2021)

Vaccine booster efficiently inhibits entry of SARS-CoV-2 omicron variant
por: Zhang, Wei, et al.
Publicado: (2022)

Protection against the Omicron Variant from Previous SARS-CoV-2 Infection
por: Altarawneh, Heba N., et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
por: Yu, Jingyou, et al.
Publicado: (2022)

Increased immune escape of the new SARS-CoV-2 variant of concern Omicron
por: Hu, Jie, et al.
Publicado: (2022)

Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients
por: Destras, Grégory, et al.
Publicado: (2022)

Liver injury caused by SARS-CoV-2 Delta and Omicron-variant in Taiwan
por: Jang, Tyng-Yuan
Publicado: (2022)

Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant
por: Yamasoba, Daichi, et al.
Publicado: (2023)

SARS-CoV-2 Omicron variant virus isolates are highly sensitive to interferon treatment
por: Bojkova, Denisa, et al.
Publicado: (2022)

SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons
por: Rössler, Annika, et al.
Publicado: (2022)

Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2
por: Antonelli, Michela, et al.
Publicado: (2022)

Structures of ACE2–SIT1 recognized by Omicron variants of SARS-CoV-2
por: Shen, Yaping, et al.
Publicado: (2022)

SARS-CoV-2 variant omicron XBB.1.5: challenges and prospects – correspondence
por: Channabasappa, Nikhil K., et al.
Publicado: (2023)

Dynamic disease manifestations among individuals infected with SARS-CoV-2 Omicron variant
por: Wang, Peiqin, et al.
Publicado: (2023)

A SARS-CoV-2 antibody retains potent neutralization against Omicron by targeting conserved RBM residues
por: Yi, Chunyan, et al.
Publicado: (2022)

A nanobody recognizes a unique conserved epitope and potently neutralizes SARS-CoV-2 omicron variants
por: Modhiran, Naphak, et al.
Publicado: (2023)

Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination
por: Yu, Xiaoqi, et al.
Publicado: (2022)

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
por: Pajon, Rolando, et al.
Publicado: (2022)

Decoupling of omicron variant infections and severe COVID-19
por: Madhi, Shabir A, et al.
Publicado: (2022)

Outcome of infection with omicron SARS‐CoV‐2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report
por: Blennow, Ola, et al.
Publicado: (2022)

Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant
por: Uriu, Keiya, et al.
Publicado: (2023)

More data needed on efficacy and safety of monovalent vaccines against SARS-CoV-2 omicron variants
por: Monach, Paul A, et al.
Publicado: (2023)

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum
por: Dejnirattisai, Wanwisa, et al.
Publicado: (2022)

Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa
por: Gray, Glenda, et al.
Publicado: (2022)

Replicative capacity of SARS-CoV-2 omicron variants BA.5 and BQ.1.1 at elevated temperatures
por: Muramoto, Yukiko, et al.
Publicado: (2023)

Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant
por: Zhao, Xin, et al.
Publicado: (2022)

Olverembatinib inhibits SARS‐CoV‐2‐Omicron variant‐mediated cytokine release in human peripheral blood mononuclear cells
por: Chan, Marina, et al.
Publicado: (2022)

Humoral and cellular immunity to SARS-CoV-2 Ancestral and Omicron BA.5 variants following vaccination in myelofibrosis patients
por: Alcheikh, Ahmad, et al.
Publicado: (2023)

Evolving spike mutations in SARS-CoV-2 Omicron variants facilitate evasion from breakthrough infection-acquired antibodies
por: Chen, Shiqi, et al.
Publicado: (2023)

Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant
por: Takashita, Emi, et al.
Publicado: (2022)

A spike protein S2 antibody efficiently neutralizes the Omicron variant
por: Hu, Jia, et al.
Publicado: (2022)

Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant
por: Higdon, Melissa M, et al.
Publicado: (2022)

Characteristics and implications of Omicron variant associated digestive system infections – Correspondence
por: Shi, Yunjie, et al.
Publicado: (2022)

Evaluation of cross-neutralizing antibodies in children infected with omicron sub-variants
por: Peng, Weiyu, et al.
Publicado: (2023)

Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection
por: Jeong, Hye Won, et al.
Publicado: (2022)

Substantial immune response in Omicron infected breakthrough and unvaccinated individuals against SARS-CoV-2 variants of concern
por: Yadav, Pragya D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_55rf5lpt49utr3152aho4u05b7